IQWiG publishes preliminary report on the guideline synopsis for the update of the DMP type 2 diabetes mellitus
On behalf of the Federal Joint Committee (G-BA), the Institute for Quality and Efficiency in Health Care (IQWiG ) has identified current evidence-based guidelines on the treatment of type 2 diabetes mellitus in order to compare their recommendations with the Disease Management Program Requirements Directive (DMP-A-RL) and identify any discrepancies. For this preliminary report, a total of 1025 recommendations from 18 current evidence-based guidelines were assigned to the care aspects of the DMP-A-RL for the DMP type 2 diabetes mellitus and compared in terms of content.
Preliminary conclusion: The currently valid appendix on type 2 diabetes mellitus in the DMP-A guidelines is largely in line with the current evidence-based guidelines. For some aspects of the DMP type 2 diabetes mellitus, it could be examined whether there is a need to adapt the DMP.
IQWiG publishes the preliminary assessment results with the aim of incorporating important arguments or comments from the expert community and all interested parties. Comments on the
Preliminary reports are possible until 04.08.2025.
IQWiG published the report plan for this project on 29.11.2024. Written comments on the preliminary report can be submitted until 04.08.2025. If these leave any questions unanswered, the respondents will be invited to an oral discussion, probably on August 29, 2025. The final report on the project will then be prepared.
Original Paper:
[V24-11] Guideline synopsis for the update of the DMP Diabetes Mellitus Type 2
The articles in the news section are produced by X-Press journalist office
Gender note. The personal designations used in this text always refer equally to female, male and diverse persons. Double/triple references and gendered designations are avoided in favor of better readability. t
Most read
Measles: Vaccination gaps in small children alarm health insurance companies A current data analysis by the posted on 18. July 2025- Hamburg becomes a pioneer: PROVIREX enables local CAR-T cell production CAR T-cell therapy has been revolutionizing the treatment of certain blood cancers in Germany since...
- Virtual shock room at Ulm University digitally enhances medical studies The Faculty of Medicine at Ulm University is introducing an innovative training method for medical s...
